Clinical trials: Apixaban
Bariatric Surgery, Obesity
Apixaban Pharmacokinetics in Bariatric Patients (APB)
The Center for Bariatric Surgery is interested in conducting a pharmacokinetic study of apixaban (an oral anticoagulant with FDA approval for use of venous thrombo embolism (VTE) prophylaxis and treatment) in the obese adult…
- Trial name
- APB (NCT02406885)
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Johns Hopkins University
Venous Thromboembolism
Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea
This study is a retrospective, observational, nationwide population-based cohort study utilizing the South Korea's Health Insurance and Review Assessment Service (HIRA) database.
- Trial name
- NCT05022563
- Testing
- Parenteral anticoagulant, Warfarin, Apixaban
- Where
- 2 sites in South Korea
- Volunteers
- 55,759 people
- Sponsor
- Pfizer
Healthy
Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT
This study is a randomized, single-blind, placebo-controlled study to assess the efficacy and safety of ciraparantag administered to healthy volunteers anticoagulated with apixaban measuring clotting times using Whole Blood…
- Trial name
- NCT03288454
- Testing
- Ciraparantag, Apixaban
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Venous Thromboembolism
Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism
Patients who have developed a venous thrombosis will receive apixaban to treat and prevent a secondary thromboembolism.
- Trial name
- VTE (NCT04041843)
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- New York Medical College
Atrial Fibrillation
Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)
Oral anticoagulant (OAC) treatment with either vitamin K antagonists (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs) is essential in patients with atrial fibrillation for the prevention of stroke or systemic…
- Trial name
- REATTAIN (NCT04249401)
- Testing
- Rivaroxaban (Xarelto), Apixaban, Dabigatran
- Where
- Sweden
- Volunteers
- 134,897 people
- Sponsor
- Bayer
Atrial Fibrillation, End Stage Renal Failure on Dialysis
Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis
The prevention of atrial fibrillation related thromboembolism in the dialysis population is unclear. While the practice of anticoagulation appears favorable in patients with mild-to-moderate chronic kidney disease, no patients…
- Trial name
- SAFE-D (NCT03987711)
- Testing
- Warfarin, Apixaban, No oral anticoagulation
- Where
- 28 sites in Australia, Canada
- Volunteers
- 151 people
- Sponsor
- Unity Health Toronto
Atrial Fibrillation (AF), Stroke (in Patients With Atrial Fibrillation)
DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial
People with atrial fibrillation who have a stroke while receiving a DOAC are at increased risk of experiencing another stroke. Physicians do not know the best medication to prevent another stroke in this group of people.
- Trial name
- SWITCH-AF (NCT07011095)
- Testing
- VKA, Direct Oral Anticoagulant (DOAC)
- Volunteers
- 100 people
- Sponsor
- Population Health Research Institute
Chronic Kidney Diseases, Atrial Fibrillation
Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation
Objective: To study the efficacy and safety of apixaban as stroke prophylaxis in patients with chronic kidney disease (CKD) stage 5 and atrial fibrillation (AF) with or without dialysis treatment.
- Conditions
- Chronic Kidney Diseases, Atrial Fibrillation, Stroke, Intracerebral Hemorrhage
- Trial name
- SACK (NCT05679024)
- Testing
- Apixaban 2.5 milligram Oral Tablet
- Where
- 34 sites in Finland, Iceland and 2 more
- Volunteers
- 1,400 people
- Sponsor
- Region Stockholm
Periprocedural Complication
Periprocedural Direct Oral Anticoagulant Management
Direct oral anticoagulants (DOAC) are a new drug group that has been approved for chronic anticoagulation of patients in atrial fibrillation or suffering acute thrombosis, between others.
- Trial name
- RA-ACOD (NCT03182218)
- Testing
- Direct oral anticoagulant
- Where
- 30 sites in Spain
- Volunteers
- 1,100 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Atrial Fibrillation
Predictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation..
Post-authorization observational, prospective, follow-up study of a cohort of patients with non-valvular atrial fibrillation who are treated with direct oral anticoagulants (DOACs) to evaluate the clinical course (occurrence of…
- Trial name
- NCT04297150
- Testing
- Apixaban, Edoxaban, Rivaroxaban
- Where
- 6 sites in Spain
- Volunteers
- 700 people
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Treatment of Venous Thromboembolism in Cancer Patients, Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients
Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort
Patients with active cancer are ~5-fold more likely to develop a venous thromboembolism (VTE) than those without. When VTE occurs, cancer patients carry an up to a 3-fold higher rate of thrombosis recurrence and ~twice the risk…
- Trial name
- OSCAR-US (NCT04979780)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Low molecular weight heparin (LMWH), Direct Oral Anticoagulants (DOAC)
- Where
- United States
- Volunteers
- 3,708 people
- Sponsor
- Bayer
Atrial Fibrillation, End-stage Kidney Disease
Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)
The Study is an open-labeled, randomized controlled trial, phase IIIb. Its objective is to assess the safety of the factor Xa inhibitor apixaban versus the vitamin-K antagonist (VKA) phenprocoumon in patients with NVAF and ESKD…
- Trial name
- AXADIA (NCT02933697)
- Testing
- Apixaban, Phenprocoumon
- Where
- Germany
- Volunteers
- 108 people
- Sponsor
- Atrial Fibrillation Network
Thromboembolism
A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer
The purpose of this study is to evaluate the health care resource utilization and costs associated with treating patients diagnosed with cancer and venous thromboembolism with apixaban or low molecular weight heparin.
- Trial name
- NCT05643885
- Where
- United States
- Volunteers
- 7,304 people
- Sponsor
- Pfizer
Takotsubo Syndrome
BROKEN-SWEDEHEART- Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome.
The aim of this study is to document an optimized pharmacologic treatment for patients with Takotsubo Syndrome. There is currently no published documentation in a large number of patients.
- Trial name
- NCT04666454
- Testing
- Adenosine, Dipyridamole 200 mg, Apixaban 5 mg Oral Tablet
- Where
- 16 sites in Denmark, Norway and 1 more
- Volunteers
- 1,000 people
- Sponsor
- Vastra Gotaland Region
Splanchnic Vein Thrombosis, Cerebral Vein Thrombosis
DOAC in Unusual Site Venous Thrombosis
Unusual site venous thromboembolism (VTE) refers to thrombosis occurring in venous districts outside the veins of the lower extremities and the pulmonary arteries, and includes splanchnic vein thrombosis (SVT), cerebral vein…
- Conditions
- Splanchnic Vein Thrombosis, Cerebral Vein Thrombosis, Ovarian Vein Thrombosis, Renal Vein Thrombosis
- Trial name
- DUST (NCT03778502)
- Testing
- Direct Oral Anticoagulants
- Where
- 24 sites in United States, Canada and 8 more
- Volunteers
- 358 people
- Sponsor
- University of Malta
Traumatic Intracranial Haemorrhage
Timing to Restart Direct Oral Anticoagulants After Traumatic Intracranial Haemorrhage
Older people falling from a standing height is the most common cause of hospital admission for head injury. Up to 1 in 3 patients admitted are taking a tablet medication which thins the blood, known as an oral anticoagulant.
- Trial name
- RESTARTtlCrH (NCT06322953)
- Testing
- Direct-Acting Oral Anticoagulants (used as per local standard practice)
- Where
- 2 sites in United Kingdom
- Volunteers
- 1,084 people
- Sponsor
- Walton Centre NHS Foundation Trust
Atrial Fibrillation
Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants
The purpose of this study is to compare the risk of major bleeding event among nonvalvular atrial fibrillation patients treated with warfarin, apixaban, dabigatran and rivaroxaban.
- Trial name
- NCT02754154
- Testing
- Warfarin, Apixaban, Dabigatran
- Volunteers
- 321,182 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation
Non-Interventional Study Describing Direct Costs Related to Anti-coagulation Treatment
To describe the direct costs related to warfarin/apixaban treatment
- Trial name
- NCT04435769
- Where
- Czechia
- Volunteers
- 109 people
- Sponsor
- Pfizer
Acute Coronary Syndrome
Phase III Acute Coronary Syndrome
The purpose of this study is to determine if apixaban is superior to placebo for preventing cardiovascular death, non-fatal myocardial infarction, or ischemic stroke in subjects with a recent acute coronary syndrome
- Trial name
- APPRAISE-2 (NCT00831441)
- Testing
- Apixaban
- Where
- 1,012 sites in United States, Argentina and 38 more
- Volunteers
- 7,484 people
- Sponsor
- Bristol-Myers Squibb
Acute Myocardial Infarction, Left Ventricular Thrombosis
Apixaban Versus Warfarin in Patients With Left Ventricular (LV) Thrombus
Patients with acute ST-segment elevation myocardial infarction (STEMI) have an elevated risk of stroke, most of which are cardio-embolic in origin as a result of left ventricular (LV) thrombus formation.
- Conditions
- Acute Myocardial Infarction, Left Ventricular Thrombosis, Anticoagulants and Bleeding Disorders
- Trial name
- NCT03232398
- Testing
- Apixaban Oral Tablet [Eliquis], Warfarin
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Hadassah Medical Organization